How to Structure Clinical Trials Agreements in Czechia Without Legal Headaches

16.3.2026 | ARROWS law firm

If you're planning to conduct clinical trials in the Czech Republic, you already know that regulatory compliance is critical. But here's what many sponsors and investigators miss: a poorly structured clinical trial agreement (CTA) can create unexpected complications that no amount of protocol compliance will fix. From payment disputes to intellectual property conflicts and liability gaps, the wrong agreement language can cost you months of delays, significant legal fees, and in worst cases, project failure.

Picture illustrates a specialist advising on clinical trial agreements.

Article contents

Why clinical trial agreements matter more than you think
Fundamental components of a Czech clinical trial agreement
Scope of work and protocol compliance
Understanding sponsor indemnification
Intellectual property rights and publication provisions
Risk management and trial termination provisions
Working with international sponsors and cross-border trial complexities

Understanding the legal environment for clinical trials agreements in Czechia

Clinical trials in the Czech Republic operate within a strictly regulated framework defined primarily by Regulation (EU) No 536/2014 (Clinical Trials Regulation - CTR), which is directly applicable in all EU Member States. The national Act No. 378/2007 Coll., on Pharmaceuticals, as amended, also plays a key role.

The State Institute for Drug Control (SUKL), operating under the Czech Ministry of Health, serves as the primary regulatory authority responsible for issuing decisions on clinical trials and monitoring compliance. However, regulatory authorization is just one piece of the puzzle.

The actual mechanics of how sponsors, investigators, and sites (Healthcare Providers) interact are governed by civil law contracts. Specifically, these fall under Act No. 89/2012 Coll., the Civil Code, and must be carefully drafted to protect all parties.

The Czech regulatory framework is fully integrated into the EU system via the CTR. Since the end of the transition period in January 2025, all clinical trials in Czechia must strictly adhere to the CTR standards.

This means that while procedural requirements for authorization are unified across Europe via the Clinical Trials Information System (CTIS), the specific civil obligations are still subject to Czech national law. What works in Germany may not protect you adequately in Czechia if the agreement language doesn't account for Czech Civil Code requirements.

Many international sponsors underestimate the differences between Czech contract law and their home jurisdictions. ARROWS Law Firm, a leading Prague-based law firm operating in the European Union, regularly handles clinical trial agreements with cross-border elements for both domestic and international clients. The lawyers at ARROWS Law Firm understand that clinical trials agreements require not just regulatory knowledge, but also commercial sensitivity and practical experience with how these agreements actually function in real-world scenarios.

Why clinical trial agreements matter more than you think

Before addressing the specific components of clinical trial agreements, it's important to understand why these documents matter so much. Many sponsors view agreements as merely administrative necessities or formalities to check off before the trial begins.

A clinical trial agreement serves multiple critical functions simultaneously. First, it defines the legal relationship between parties (sponsor, healthcare provider/site, and investigator). Second, it allocates financial obligations and payment terms regarding the Fair Market Value (FMV) of services.

Third, it establishes liability frameworks and indemnification provisions in line with Section 52 of the Act on Pharmaceuticals. Finally, it creates a binding framework for compliance with Good Clinical Practice (GCP) and GDPR standards.

When any of these elements is poorly drafted or misaligned with other provisions, conflicts emerge. For example, a sponsor may believe it has indemnification protection for serious adverse events, only to discover that the site's insurance doesn't cover those specific scenarios.

The complexity here extends far beyond what appears in the contract language itself. Individual provisions interact with Czech law, EU regulations, applicable insurance requirements, tax law, and the particular operational realities of the site.

ARROWS Law Firm's lawyers have found that many agreements that appear reasonable on their surface contain hidden time bombs that only detonate once the trial is underway. This is why the expertise at ARROWS Law Firm in handling these agreements daily significantly reduces the time spent by clients and minimizes the risk of costly errors.

Fundamental components of a Czech clinical trial agreement

A properly structured clinical trial agreement in Czechia addresses several essential elements that must be carefully balanced and integrated. Understanding what belongs in each section and how these sections interact is fundamental to creating an agreement that actually protects your interests.

Defining the parties and their roles

The first critical step is precisely defining who the parties are and what role each party plays. This contains important nuances in Czech practice. The agreement should identify the Sponsor, the Provider of Health Services (the site/hospital), and the Principal Investigator.

Czech law distinguishes between the Provider (the legal entity, e.g., University Hospital) and the Investigator (usually an employee) as distinct entities. Under Czech law, the primary contract must be with the Provider (the hospital), as they hold the authorization to provide health services.

The Investigator is typically a party to the agreement or signs a separate statement of responsibility, but the financial and liability relationship is primarily between the Sponsor and the Provider.

If the sponsor is established outside the European Union, Article 74 of the CTR requires the appointment of a Legal Representative in the Union. The agreement must clearly reflect this structure. While a Contract Research Organization (CRO) often manages the trial, the Sponsor remains ultimately responsible for the trial data and participant safety.

microFAQ – Legal tips on defining parties in Czech clinical trial agreements

1. What is the difference between a sponsor and a CRO in Czech clinical trial agreements? A sponsor is the organization that initiates, funds, and takes overall responsibility for the trial. A CRO (Contract Research Organization) is a service provider that manages specific operational aspects on behalf of the sponsor. While a CRO may sign the agreement based on a Power of Attorney, the Sponsor retains ultimate legal responsibility under the CTR and Act on Pharmaceuticals.

2. Can a single agreement cover both the institution and the investigator, or do we need separate agreements? A single tripartite agreement (Sponsor – Provider – Investigator) is the most common and recommended structure in Czechia. It clearly links the Investigator's duties to the Provider's facilities. Separate agreements are possible but risky, as they can create conflicting obligations regarding time allocation and liability.

3. What happens if the investigator changes during the trial? The agreement should include provisions for investigator substitution. Under the CTR, a change of the Principal Investigator is considered a "substantial modification" (Part II) and must be notified via CTIS. The agreement must require the new investigator to assume all obligations of the previous investigator, typically through an amendment or accession agreement.

Scope of work and protocol compliance

The agreement must clearly define the scope of the clinical trial being conducted, incorporating essential information from the protocol while remaining appropriately distinct from the protocol itself. The protocol describes the scientific design, while the agreement describes the legal and financial framework.

In practice, the agreement should reference the protocol by version number and date (or EudraCT/EU Trial number). The agreement must explicitly commit the Provider and Investigator to conducting the trial in accordance with the approved protocol, the CTR, the Act on Pharmaceuticals, and Good Clinical Practice (GCP) standards.

A critical element is the treatment of substantial modifications (formerly amendments). During the course of a trial, the sponsor may modify the protocol. The agreement should specify that investigators will not implement substantial modifications until the appropriate authorization has been issued.

Regulatory approvals and ethics committee requirements

Since the full implementation of the CTR, the approval process in Czechia is centralized via the Clinical Trials Information System (CTIS). There is no longer a separate independent submission to the Ethics Committee and SUKL in the traditional sense.

In Czechia, SUKL issues the final administrative decision, which incorporates the binding opinion of the designated Ethics Committee. While the Sponsor is responsible for the CTIS submission, the Site is typically responsible for providing site-specific documents for the Part II assessment.

The agreement should specify that the trial cannot commence at the site until the Sponsor provides the "Notification of Decision" generated by CTIS confirming authorization.

Czech law requires that participant-facing documentation (Informed Consent Form - ICF) be in the Czech language. ARROWS Law Firm regularly advises clients on the documentation required for successful Part II submissions in Czechia. The lawyers at ARROWS Law Firm can guide both sponsors and sites on navigating the regulatory approval process.

microFAQ – Legal tips on regulatory approvals and Ethics Committee requirements

1. Can a site begin enrolling participants before the final decision is issued via CTIS? No. Under the CTR and Czech Act on Pharmaceuticals, the trial is authorized only after the decision is issued via CTIS. The agreement must explicitly state that enrollment cannot begin until this authorization is confirmed and the site initiation visit has occurred.

2. Who is responsible if the Ethics Committee requires amendments to the informed consent form? During the Part II assessment via CTIS, the Ethics Committee may request information (RFI). The Sponsor is responsible for answering via CTIS, but the Site must cooperate immediately to provide local context. The agreement should mandate strict timelines for the Site to assist with these RFIs to avoid lapsed deadlines in CTIS.

3. What if the trial is authorized with conditions? The agreement should specify that if regulatory authorization is granted with conditions, all parties will collaborate to fulfill them. If conditions cannot be met, the agreement should allow for termination without penalty.

Financial arrangements and payment structures

Financial issues are among the most contentious areas. The Czech Act on Pharmaceuticals requires that financial arrangements between the Sponsor and the Investigator/Provider be transparent and not induce the prescription of medicinal products.

Establishing fair compensation

The agreement must establish what services are being compensated and at what rate. Payments must reflect Fair Market Value (FMV) to comply with anti-bribery and anti-kickback laws.

Modern best practices recommend budgeting at the procedural level—identifying specific tasks and establishing compensation for each task. The agreement must also clearly distinguish between "Standard of Care" (reimbursed by public health insurance) and "Research Costs" (paid by the Sponsor).

Compensation for investigator and coordinator time during investigator meetings should be addressed. Current practice increasingly recognizes that sponsors should reimburse site staff time spent in mandatory training, as this is work performed for the Sponsor.

Payment terms and invoice processing

The timing and mechanics of payment create significant practical challenges. Under Czech VAT law, clinical trial services are generally considered taxable supplies. The agreement must clearly state whether amounts are VAT-exclusive or inclusive.

Recent industry trends encourage shorter payment cycles, typically 30 to 60 days. The agreement should specify clearly what constitutes a "correct invoice" and legally required VAT elements.

ARROWS Law Firm has found that many payment disputes in Czech clinical trials arise from disagreement about whether work was properly documented in the eCRF (Electronic Case Report Form). The agreement should establish that payments are triggered by verified data entry in the eCRF.

Risks and sanctions	How ARROWS (office@arws.cz) helps
Payment disputes and delays: Extended payment cycles and unclear invoice validation procedures create financial strain on sites.	Budget negotiation and structuring: ARROWS helps sponsors and sites establish clear, objective payment procedures and budget structures that align compensation with actual work performed.
Double Funding Risks: Billing the Sponsor for procedures covered by public health insurance constitutes fraud.	Compliance review: ARROWS assists in distinguishing between research costs and standard of care in the contract to ensure compliance with Czech insurance laws.
Regulatory findings on financial conflicts of interest: Poorly structured payments can create the appearance of inappropriate financial inducements.	Anti-kickback compliance: ARROWS ensures payment structures comply with Czech regulations and industry codes (AIFP), avoiding regulatory red flags.
Tax/VAT complications: Incorrect application of VAT or Reverse Charge rules can lead to penalties from the Czech Financial Administration.	Tax-compliant payment structuring: ARROWS incorporates Czech tax law requirements into payment provisions, ensuring VAT and withholding tax are handled correctly.
Trial termination with unpaid invoices: Incomplete invoicing procedures leave sites with valid work that cannot be properly paid if the trial ends prematurely.	Termination payment provisions: ARROWS ensures agreements include clear procedures for validating and paying for work completed up to trial termination.

Liability, indemnification, and insurance requirements

This is the most legally complex area. Liability provisions establish who bears financial responsibility if participants are harmed.

Under Section 52(3) of the Act on Pharmaceuticals, the Sponsor is objectively liable for damage caused to the trial subject as a result of the clinical trial. This is a strict liability standard regarding the investigational medicinal product (IMP) and trial procedures.

The Sponsor typically indemnifies the Site and Investigator against liability arising from the trial, except in cases of site negligence or non-compliance. The challenge is drafting indemnification language to clarify this boundary.

ARROWS Law Firm helps both sponsors and investigators navigate these complex distinctions to ensure the contract reflects the mandatory Czech statutory liability framework. If you need guidance negotiating indemnification provisions, contact office@arws.cz.

Site and investigator indemnification obligations

Sites are typically asked to indemnify sponsors for harm arising from site negligence, protocol deviations, or non-compliance. In Czechia, the Provider (Hospital) bears liability for the professional conduct of its employees. Therefore, the indemnification obligation usually rests with the Provider.

Insurance requirements

Section 52(3) of the Act on Pharmaceuticals and Article 76 of the CTR mandate that the Sponsor must secure compensation for damage suffered by a subject. This requires the Sponsor to hold specific clinical trial insurance.

The Site (Provider) is required by law to maintain general professional liability insurance (medical malpractice). The agreement should acknowledge this multi-layer insurance: Sponsor insurance covers trial-specific risks, while Site insurance covers standard medical malpractice.

Intellectual property rights and publication provisions

Intellectual property issues often cause disputes regarding who owns trial data and who can publish findings.

Ownership of trial data and inventions

The agreement must clearly establish that the Sponsor owns the clinical trial data (CRF data) and has rights to use that data for regulatory submissions. This is standard under the Civil Code provisions on works made for hire or specific assignment clauses.

However, according to Czech law and GDPR, the medical records (source documents) remain the property of the Provider and the data of the patient. The Sponsor receives only pseudonymized data.

If the trial generates patentable inventions, the agreement typically assigns these to the Sponsor. However, for academic sites, mandatory internal regulations regarding intellectual property of university hospitals must be respected.

Publication rights and timelines

Investigators generally retain the right to publish, but this right is balanced against the Sponsor's IP interests. The agreement typically allows the Sponsor a review period to check for inadvertent disclosure of confidential information or to file patent applications.

Crucially, Article 81 of the CTR requires the Sponsor to publish a summary of results in the EU database within one year of the end of the trial. The agreement cannot contradict this statutory transparency obligation.

Informed consent, data protection, and ethical compliance

Informed consent is a fundamental requirement under Article 28 of the CTR. The participant must sign and date the ICF before any trial-specific procedure. The agreement must require the Investigator to document this process perfectly.

Participants have the right to withdraw at any time. The agreement should specify that upon withdrawal, no further data will be collected, but data already collected may be processed to ensure the reliability and safety of the trial.

Clinical trials involve processing sensitive health data. The agreement must address GDPR and the Czech Act No. 110/2019 Coll., on Personal Data Processing.

A critical distinction in Czech law is that the legal basis for processing personal data in a clinical trial is usually not consent (Art. 6(1)(a) GDPR). Instead, it relies on Legal Obligation (Art. 6(1)(c) GDPR) for safety reporting and Public Interest/Scientific Research (Art. 6(1)(e) or (f) GDPR) for the research purpose itself.

The "Informed Consent" signed by the patient is an ethical requirement for participation, distinct from the GDPR legal basis. The Sponsor and Site usually act as independent controllers or joint controllers, depending on the specific trial design.

Amendments, protocol deviations, and trial modifications

Protocol modifications

Modifications are now managed via CTIS. The agreement should specify that the Sponsor manages the regulatory submission of "substantial modifications" (Part I and II) and informs the Site immediately upon authorization.

Protocol deviations and reporting

The agreement must establish that deviations must be documented. Under the CTR, serious breaches of the Regulation or protocol that affect safety or data integrity must be reported to SUKL without delay (within 7 days). The agreement must place a strict obligation on the Investigator to report such breaches to the Sponsor immediately so the Sponsor can meet the statutory reporting deadline.

Risk management and trial termination provisions

Trial termination and data archiving

When a trial ends, the CTR (Article 58) requires the Sponsor and the Investigator to archive the content of the clinical trial master file for at least 25 years after the end of the trial.

This is a massive logistical burden as most Czech hospitals do not have 25-year storage capacity. The agreement must clearly state who pays for archiving and whether the Site will use an external archival service.

Failure to secure 25-year archiving is a frequent finding in SUKL inspections. The agreement must also include the procedure for notifying the Sponsor before any destruction of documents.

Risks and sanctions	How ARROWS (office@arws.cz) helps
Regulatory rejection of trial: Poorly drafted agreements that fail to align with CTIS procedures create confusion about regulatory responsibilities.	Regulatory compliance review: ARROWS ensures agreement language aligns with the CTR and Czech Act on Pharmaceuticals.
Serious Breach Reporting: Failure to report serious breaches within 7 days can lead to significant penalties from SUKL.	Protocol establishment: ARROWS helps establish clear reporting lines in the contract to ensure statutory deadlines are met.
Archiving Violations: Agreements silent on the 25-year archiving rule expose both parties to penalties.	Archiving provision drafting: ARROWS ensures agreements clearly allocate the 25-year data archiving responsibility and costs.
Premature termination: Trials terminated early require specific close-out payments.	Termination payment procedures: ARROWS incorporates termination provisions protecting sites' financial interests if trials end early.
Intellectual property conflicts: Unclear IP ownership leads to disputes over patent rights.	IP provision clarification: ARROWS helps negotiate clear IP provisions establishing ownership and publication rights.

Working with international sponsors and cross-border trial complexities

If the Sponsor is not established in the EU, they must appoint a natural or legal person established in the Union as a legal representative (Article 74 CTR). This representative ensures compliance with the Regulation.

The agreement must identify this representative, as they share liability for compliance. ARROWS Law Firm regularly acts as or advises legal representatives and navigates these jurisdictional issues.

Currency and governing law

Contracts with international sponsors often propose foreign law (e.g., New York Law or English Law). While Czech law allows choice of law, mandatory provisions of Czech law regarding liability to patients and safety reporting will typically prevail.

It is generally recommended that the agreement be governed by Czech law, or at minimum, that the dispute resolution clause allows for practical arbitration or litigation. Mandatory provisions of Czech law will typically prevail over foreign law regarding the trial conduct in Czechia.

Executive summary for management

Clinical trial agreements in the Czech Republic require careful attention to the Clinical Trials Regulation (EU) 536/2014, the Act on Pharmaceuticals, and the Civil Code.

Regulatory Framework: The transition to the CTR is complete. Agreements must reflect the single decision process via CTIS and the unified EU assessment.
Payment Structures: Must be FMV, VAT-compliant, and clearly distinguish between research costs and standard of care to avoid insurance fraud.
Liability: Sponsors carry strict statutory liability for trial damages. Indemnification clauses must align with Section 52 of the Act on Pharmaceuticals.
Archiving: The 25-year archiving obligation is non-negotiable and requires specific contractual and financial provisions.
GDPR: The legal basis for processing is rarely consent; agreements must reflect the correct GDPR articles and the Joint Controller relationship where applicable.

Conclusion of the article

Clinical trial agreements in Czechia are legally complex instruments that bridge EU regulations, national health laws, and commercial interests. Relying on templates from other jurisdictions or pre-CTR era contracts is a significant risk.

The lawyers at ARROWS Law Firm have extensive experience structuring clinical trial agreements in Czechia for sponsors, sites, and investigators under the current 2026 legal framework. ARROWS Law Firm's lawyers understand not just the legal requirements but the practical operational realities that determine whether agreements actually function as intended.

ARROWS Law Firm provides comprehensive services in this area, including representation in all stages of clinical trial agreement negotiation, compliance review under the CTR, and professional representation before SUKL.

To ensure your clinical trial agreement properly protects your interests and complies with Czech regulatory requirements, contact office@arws.cz and discuss your specific circumstances with our experienced team.

FAQ – Frequently asked legal questions about clinical trial agreements in Czechia

1. If we use a CRO to manage the clinical trial, does the CRO need to be party to the agreement with the site? The Sponsor retains ultimate responsibility. However, a CRO often signs "on behalf of the Sponsor" based on a Power of Attorney. If the CRO signs in its own name, the agreement must clearly transfer liability back to the Sponsor as required by the CTR.

2. What is the typical timeline for executing a clinical trial agreement? Contract negotiation typically runs parallel to the Part I and Part II assessment in CTIS. The goal is to have the contract signed by the time the CTIS decision is issued (approx. 60-106 days depending on RFIs).

3. Our investigator is retiring. Do we need a new agreement? A change of Principal Investigator is a substantial modification requiring notification in CTIS. An amendment to the contract or an accession agreement for the new investigator is legally required.

4. What if the site experiences financial difficulties? The agreement should allow the Sponsor to terminate for "anticipated breach" or insolvency to protect participant safety and data integrity.

5. We're concerned about data security. The agreement should reference ISO 27001 standards or specific technical measures (pseudonymization) and require the Site to report any personal data breaches to the Sponsor within 24 hours to allow GDPR compliance.

Disclaimer: The information contained in this article is for general informational purposes only and serves as a basic guide to the issue as of 2026. Although we strive for maximum accuracy, laws and their interpretation evolve over time. We are ARROWS Law Firm, a member of the Czech Bar Association (our supervisory authority), and for the maximum security of our clients, we are insured for professional liability with a limit of CZK 400,000,000. To verify the current wording of the regulations and their application to your specific situation, it is necessary to contact ARROWS Law Firm directly (office@arws.cz). We are not liable for any damages arising from the independent use of the information in this article without prior individual legal consultation.